Iowa Diabetes and Endocrinology Research Center | West Des Moines, IA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Have type 1 diabetes
Have a history of chronic or acute pancreatitis
Have a history of
Have any of these cardiovascular (CV) conditions within 60 days prior to screening:
Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies
Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)
Have been treated with insulin prior to screening
Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation
Primary purpose
Allocation
Interventional model
Masking
282 participants in 2 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal